In-Hospital COPD Deaths Plummet by 62% Between 2005 and 2014

Between 2005 and 2014, there was a dramatic dip in the number of patients with chronic obstructive pulmonary disease (COPD) who died in the hospital, according to new data presented at the 2017 American Thoracic Society International Conference.
 
The investigators analyzed the Healthcare Cost and Utilization Project Nationwide Inpatient Sample, a database that contains 95% of all hospital discharges in the United States.
 
The results of the study showed that during this period, there were 8,575,820 hospitalizations for COPD-related health issues. Of these hospitalizations, the number of patients who died in the hospital decreased from 24,226 to 9090––a 62% decrease.
 
“This is certainly an encouraging trend,” said lead author Khushboo Goel, MD. “We expected to see a decline because of improvements in caring for conditions such as pneumonia, sepsis, septic shock, and thromboembolic diseases associated with COPD exacerbations, but the magnitude of the decline in mortality was surprising.”
 
This trend was found to be true among White, Black, and Hispanic patients, the authors noted.
 
Most notably, the investigators found that women accounted for most of the hospitalizations and in-hospital deaths each year, making up 58% of the hospitalizations and 51% to 55% of in-hospital deaths.
 
“Our studies suggest possible explanations for the higher COPD burden women in the US have,” Dr Goel said. “Including the growing number of women who smoke, the increased severity of symptoms they may experience, and longer life expectancy.”
 
Additional findings included: the average age of patients hospitalized remained nearly constant at 67 years of age; the number of COPD patients treated at teaching hospitals increased from 212,346 to 371,215; and the average length of a hospital stay decreased from 5.2 days to 4.2 days.
 
COPD was the third leading cause of death in the United States in 2014, according to the CDC. Tobacco smoke is a key factor to the disease’s development and progression, although exposure to air pollutants, genetic factors, and respiratory infections also play a role.
 
Indoor air quality is believed to play a larger role in the development and progression of CODP in the developing world compared with the United States, the CDC reported. 


Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

Ocrelizumab showed a sustained reduction in underlying disease activity and improved cognitive function in patients with relapsing multiple sclerosis.
The study aimed to analyze whether age, gender, socioeconomic factors, comorbidity, and medication may affect the risk of lung cancer in patients with COPD.
Ibrutinib plus obintuzumab improved progression-free survival in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$